Early Phase 1 Hepatitis C Trial, Recruiting NCT06159504 Sponsor: Médecins du Monde Condition: Hepatitis C
Back to Hepatitis C

Early Phase 1 Hepatitis C Trial, Recruiting

NCT06159504
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who are able and willing to give their consent to participate in the local language
  • People who have never received treatment for hepatitis C
  • People who attend the trial site for a needle or syringe program, or who have injected drugs at some point in their life

Who may not be able to join:

  • People who report having severe liver disease (known as decompensated cirrhosis)
  • People who are pregnant or breastfeeding
  • People who report having other serious health conditions, such as uncontrolled HIV, kidney problems, tuberculosis, or chronic hepatitis B
  • People who are unwilling or unable to stop taking certain medications or supplements that are not safe to take alongside the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Margaret Hellard, Burnet

Phone: +61 413 272 698

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Médecins du Monde
Registry
ClinicalTrials.gov
Start date
3 October 2024
Est. completion
1 December 2026

Where this trial is recruiting

Armenia

Primary endpoints

The feasibility of implementing a hepatitis C simplified care (Arm 1) and same-day treatment (Arm 2) care models in community and harm reduction settings in the three study countries.; The proportion of participants initiating hepatitis C treatment in simplified care Arm vs same-day treatment Arm.; The proportion of participants who achieve SVR following hepatitis C treatment in simplified care Arm vs same-day treatment Arm.; The comparative cost and cost-effectiveness of simplified care vs same-day treatment models of care.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov